Overview of Business Performance
On September 14, 2016, Bayer signed a definitive merger agreement with Monsanto Company, headquartered in St. Louis, Missouri, United States, for US$128 per share. This represents a transaction value of around US$66 billion. At a special meeting on December 13, 2016, Monsanto’s stockholders approved the company’s merger with a wholly owned subsidiary of Bayer AG. The agreed acquisition reinforces our leadership position as a Life Science Life Sciences This term describes Bayer’s activities in health care and agriculture and comprises the Bayer Group excluding its legally independent subsidiary Covestro. It refers to the businesses of the Pharmaceuticals, Consumer Health and Crop Science divisions and the Animal Health business unit. company and is a major strategic step forward for our Crop Science business. The transaction is subject to customary closing conditions, including receipt of required approvals from the relevant antitrust and other authorities. We expect closing of the transaction by the end of 2017.